Yuri Mackeyev

Yuri Mackeyev, PhD is an Assistant Professor at UTHealth Houston, where he works in Dr. Krishnan's research group. His academic journey began with a PhD in Physical Chemistry from Lomonosov's Moscow State University, focusing on fluorinated [60]fullerenes. Before entering academia, he worked as a high school chemistry teacher from 1985 and received six George Soros's Open Society Foundation teaching awards (1996-2001). In 2003, he joined Prof. L.J. Wilson's lab at Rice University to research water-soluble [60]fullerene derivatives and functionalized carbon nanotubes for healthcare applications.

Dr. Mackeyev's research occupies an interdisciplinary space between organic chemistry, nanomaterials chemistry, and clinical cancer research. His primary focus is on applications of gold nanoparticles for tissue radiosensitization, imaging, and image-guided cancer therapies. Another significant research direction involves planning and conducting the synthesis of custom [60]fullerene conjugates with anticancer drugs to define better therapeutic targets at the molecular level within cancer cells and tumor vasculature. His work has resulted in over 20 publications in the past decade, primarily focused on medical applications of nanomaterials including gold nanoparticles, carbon nanotubes, graphene nanoribbons, [60]fullerene, and fluorescently-tagged polymeric composites.

Analysis of Dr. Mackeyev's recent publications reveals a consistent focus on enhancing cancer treatment through nanotechnology, particularly in improving radiation therapy outcomes. His work spans from fundamental nanomaterial synthesis to preclinical testing in cancer models, with a strong emphasis on translational potential. Key themes include targeted nanoparticle delivery systems, multimodal theranostic approaches, and understanding the mechanisms by which nanomaterials interact with biological systems to enhance cancer therapies.

• Six George Soros's Open Society Foundation annual awards for teaching (1996-2001)

Dr. Mackeyev's research program involves collaborations across disciplines, working with clinicians, physicists, and other scientists to develop innovative cancer treatments. His work in Dr. Krishnan's group at UTHealth Houston represents a significant contribution to the growing field of nanomedicine for cancer therapy, with potential to improve patient outcomes through more effective and targeted treatments.